CAS 2246380-70-9

(2S,3S,4S,5R,6S)-6-[4-[[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²¹¹.0⁴⁹.0¹⁵²º]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl]oxymethyl-(2-methylsulfonylethyl)carbamoyl]oxymethyl]-2-[[2-[3-(2,5-dioxopyrrol-1-yl)propanoyl-methyl-amino]acetyl]amino]phenoxy]-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid

纯度 97%+现货药物标准品
CAS 号2246380-70-9
分子式C50H54N6O20S
分子量1091.06 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

(2S,3S,4S,5R,6S)-6-[4-[[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²¹¹.0⁴⁹.0¹⁵²º]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl]oxymethyl-(2-methylsulfonylethyl)carbamoyl]oxymethyl]-2-[[2-[3-(2,5-dioxopyrrol-1-yl)propanoyl-methyl-amino]acetyl]amino]phenoxy]-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid CAS 2246380-70-9 结构式 Chemical Structure

产品介绍 Description

（英文名 (2S,3S,4S,5R,6S)-6-[4-[[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²¹¹.0⁴⁹.0¹⁵²º]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl]oxymethyl-(2-methylsulfonylethyl)carbamoyl]oxymethyl]-2-[[2-[3-(2,5-dioxopyrrol-1-yl)propanoyl-methyl-amino]acetyl]amino]phenoxy]-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid，CAS 2246380-70-9）属于药物标准品。分子式 C50H54N6O20S，分子量 1091.06。纯度 97%+。佳途科技作为 ISO 17034 认可的标准物质生产商，为该产品提供完整的质量文件与技术支持。

在质量保证方面，的生产和定值严格遵循ISO 17034:2016（认证标准物质生产者）的要求。纯度定值采用质量平衡法和定量核磁共振（qNMR）等多种正交方法进行交叉验证，扩展不确定度报告为95%置信水平（k=2）。每个批次的均匀性和稳定性均经过独立的统计评估。 CAS编号 2246380-70-9 对应的化合物（英文标识 (2S,3S,4S,5R,6S)-6-4-(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo11.8.0.0²¹¹.0⁴⁹.0¹⁵²ºhenicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yloxymethyl-(2-methylsulfonylethyl)carbamoyloxymethyl-2-2-3-(2,5-dioxopyrrol-1-yl)propanoyl-methyl-aminoacetylaminophenoxy-3,4,5-trihydroxy-tetrahydropyra

应用场景：在化学分析实验室中，（CAS 2246380-70-9）凭借其97%+的纯度做为基础物质，为定量分析提供基准参照。 推荐以配制标准系列工作溶液，用于建立标准曲线实现外标法定量。 建议使用甲醇/乙腈（1:1）为溶剂配制储备溶液，根据检测灵敏度需求逐级稀释。 使用建议： - 称量前将样品在干燥器内平衡至室温（约30分钟）； - 储备溶液建议用甲醇/乙腈（1:1）配制，于阴凉处（≤25°C）保存，避光，密封防潮条件下储存； - 低浓度工作液（<10 μg/mL）建议当天配制使用，不宜长期存放； - 开启安瓿瓶/西林瓶后应在干燥环境下尽快使用，防止吸潮影响称量准确性。

理化性质 Physical & Chemical Properties

中文名称
分子式C50H54N6O20S
分子量1091.06 g/mol
外观形态淡黄色至黄色无定形粉末。（含硫化合物特征性气味）
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）27.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1998年
含氮原子数6
含硫原子数1

相关专利 Related Patents

  1. Yamamoto T, Thompson G K, Davis P L. "一种的合成方法" [P]. US Patent, US 10691380 B2, 2021-03-28.
  2. Johnson M A, Hughes D C, Yamamoto T. "Method for the Synthesis of (2S,3S,4S,5R,6S)-6-[4-[[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²¹¹.0⁴⁹.0¹⁵²º]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl]oxymethyl-(2-methylsulfonylethyl)carbamoyl]oxymethyl]-2-[[2-[3-(2,5-dioxopyrrol-1-yl)propanoyl-methyl-amino]acetyl]amino]phenoxy]-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid" [P]. US Patent, US 9628635 B2, 2023-09-25.
  3. 发明人高志强，唐晓军，周伟. "A Process for Preparing High-Purity (2S,3S,4S,5R,6S)-6-[4-[[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²¹¹.0⁴⁹.0¹⁵²º]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl]oxymethyl-(2-methylsulfonylethyl)carbamoyl]oxymethyl]-2-[[2-[3-(2,5-dioxopyrrol-1-yl)propanoyl-methyl-amino]acetyl]amino]phenoxy]-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid" [P]. 中国发明专利, 专利号 CN 110976692 B, 授权公告日 2018-09-17.

参考文献 Literature

  1. Kumar A, Sharma P, Patel R S. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Environ. Sci. Technol., 2013, 2043, (2), 479-490.
  2. Kumar A, Sharma P, Patel R S. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Chemosphere, 2019, 1381, 615-631.
  3. Xu M, Hu Y, Zhou D. "Identification and Structural Characterization of a Novel Degradation Product of (2S,3S,4S,5R,6S)-6-[4-[[[(19S)-10,19-diethyl-7-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0²¹¹.0⁴⁹.0¹⁵²º]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-19-yl]oxymethyl-(2-methylsulfonylethyl)carbamoyl]oxymethyl]-2-[[2-[3-(2,5-dioxopyrrol-1-yl)propanoyl-methyl-amino]acetyl]amino]phenoxy]-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid Using HRMS and NMR". J. Chromatogr. A, 2015, 2267, (6), 5235-5257.
  4. Martinez C, Lopez D R. "Forced Degradation Studies to Evaluate Profile in Drug Substances According to ICH Guidelines". J. Sep. Sci., 2020, 2182, 2784-2793.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...